NCT02383771View on ClinicalTrials.gov

Reversal of the Anti-platelet Effects of Ticagrelor

PHASE4CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

December 31, 2016

Conditions
Coronary Artery Disease
Interventions
DRUG

Ticagrelor

(Ticagrelor 90mg Bid) x 7days

DRUG

Aspirin + Ticagrelor

(Aspirin 100mg daily + Ticagrelor 90mg Bid) x 7days

DRUG

Control

No Anti-platelet Therapy

DRUG

Aspirin + Ticagrelor

Dual anti-platelet therapy (Aspirin 100mg daily + Ticagrelor 90mg Bid) after percutaneous coronary intervention (PCI)

Trial Locations (1)

210029

First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
collaborator

National Natural Science Foundation of China

OTHER_GOV

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT02383771 - Reversal of the Anti-platelet Effects of Ticagrelor | Biotech Hunter | Biotech Hunter